Ligand Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Ligand Pharma (LGND) Tops Q2 EPS by 24c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
August 3, 2020 7:37 AM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.00, $0.24 better than the analyst estimate of $0.76. Revenue for the quarter came in at $41.4 million versus the consensus estimate of $31.39 million.
Outstanding second quarter financial results and operating execution have laid the foundation for our strong outlook for the rest of 2020 and beyond. We... More
